LNLuiza Cristine Diniz Neri

Luiza Cristine Diniz Neri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luiza Cristine Diniz Neri has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microglia-Targeted Nanotherapeutics in Major Depressive Disorder: An Integrative Perspective on Neuroinflammation and Drug Delivery

    by Pablo R. da Silva, Nayana M. M. V. Barbosa, Joandra M. da Silva Leite, Larissa P. Alves, Jéssica C. de Andrade, Allessya L. D. Formiga, Ana Flávia C. Uchôa, Luiza C. D. Neri, Arthur Lins Dias, Adriana M. F. de Oliveira-Golzio, et al.

    Major depressive disorder (MDD) is a highly prevalent psychiatric condition characterized by complex neurobiological mechanisms, including oxidative stress and neuroinflammation, with microglial activation playing a key role in its pathophysiology. Conventional antidepressants, though widely used, often fail to achieve remission due to limited efficacy, adverse effects, and poor patient adherence. In this context, nanotechnology-based drug delivery systems have emerged as promising strategies to overcome pharmacological limitations, enhance blood–brain barrier (BBB) penetration, and target neuroinflammatory pathways. This narrative review explores the role of microglia as both mediators of neuroinflammation and potential therapeutic targets in MDD. We examine different nanocarriers and their ability to modulate microglial activation, promote a shift from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, and enhance antidepressant efficacy. Preclinical studies have demonstrated that nanoparticle-based systems not only improve drug bioavailability and brain targeting but also potentiate neuroprotective effects by reducing oxidative stress, promoting neurogenesis, and restoring synaptic plasticity. These findings highlight the potential of nanotechnology as a novel approach to precision neuropsychopharmacology. This review aims to provide an integrative perspective on how nanocarrier-based strategies targeting microglia could redefine future therapeutic paradigms for MDD.


  • Open Access

    Targeting Microglia Via Nanotechnology: A Novel Strategy to Overcome Neuroinflammation in Major Depressive Disorder

    by Pablo R. da Silva, Nayana M. M. V. Barbosa, Joandra M. da Silva Leite, Larissa P. Alves, Jéssica C. de Andrade, Allessya L. D. Formiga, Ana Flávia C. Uchôa, Luiza C. D. Neri, Adriana M. F. de Oliveira-Golzio, Francisco H. Xavier-Júnior, et al.

    Major Depressive Disorder (MDD) is a highly prevalent psychiatric condition characterized by complex neurobiological mechanisms, including oxidative stress and neuroinflammation, with microglial activation playing a key role in its pathophysiology. Conventional antidepressants, though widely used, often fail to achieve remission due to limited efficacy, adverse effects, and poor patient adherence. In this context, nanotechnology-based drug delivery systems have emerged as promising strategies to overcome pharmacological limitations, enhance blood–brain barrier penetration, and target neuroinflammatory pathways. This narrative review explores the role of microglia as both mediators of neuroinflammation and potential therapeutic targets in MDD. We examine different nanocarriers — such as polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, magnetic nanoparticles, and liposomes — and their ability to modulate microglial activation, promote a shift from a pro-inflammatory (M1) to an anti-inflammatory (M2) phenotype, and enhance antidepressant efficacy. Preclinical studies have demonstrated that nanoparticle-based systems not only improve drug bioavailability and brain targeting but also potentiate neuroprotective effects by reducing oxidative stress, promoting neurogenesis, and restoring synaptic plasticity. These findings highlight the potential of nanotechnology as a novel approach to precision neuropsychopharmacology. This review aims to provide an integrative perspective on how nanocarrier-based strategies targeting microglia could redefine future therapeutic paradigms for MDD.

  • Open Access

    The Role of the Clinical Pharmacist in the Implementation of Antimicrobial Stewardship Programs

    by Maria Clara Ferreira Gonçalves, André Luiz Leocádio De Souza Matos, Bárbara Fernandes Araújo Rodrigues, Luiza Cristine Diniz Neri, Hugo Fernandes Oliveira Pires

    Book Brazil in Advancing Pharmacotherapy and Clinical Pharmacy in Latin America Proceedings of the Fourth Brazilian Congress of Pharmacotherapy and Clinical Pharmacy doi: 10.62922/4cbffc ISBN: 978-65-983944-2-4 Editors Wallace Entringer Bottacin – ORCID | Lattes | Google Scholar Thaís Teles de Souza – ORCID | Lattes Walleri Christini Torelli Reis – ORCID | Lattes | Google […]

  • Open Access

    Clinical Pharmacist's Role in Managing Patients with Chronic Kidney Disease: a Review

    by Maria Clara Ferreira Gonçalves, André Luiz Leocádio De Souza Matos, Bárbara Fernandes Araújo Rodrigues, Luiza Cristine Diniz Neri, Hugo Fernandes Oliveira Pires

    Book Brazil in Advancing Pharmacotherapy and Clinical Pharmacy in Latin America Proceedings of the Fourth Brazilian Congress of Pharmacotherapy and Clinical Pharmacy doi: 10.62922/4cbffc ISBN: 978-65-983944-2-4 Editors Wallace Entringer Bottacin – ORCID | Lattes | Google Scholar Thaís Teles de Souza – ORCID | Lattes Walleri Christini Torelli Reis – ORCID | Lattes | Google […]